Yield10 Bioscience Announces First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Take-Two stock drops as GTA 6 leaks continue
- GameStop posts higher income despite revenue drop in Q2 2026
- At least eight die, 18 missing after ferry capsizes off North Cyprus
- Goldman Sachs raises humanoid robot forecast, sees auto role
- PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
Yield10 Bioscience, Inc. (YTEN) Misses Q1 EPS by 5c, Revenues Miss
May 11, 2021 4:41 PM EDTYield10 Bioscience, Inc. (NASDAQ: YTEN) reported Q1 EPS of ($0.60), $0.05 worse than the analyst estimate of ($0.55). Revenue for the quarter came in at $196 thousand versus the consensus estimate of $220 thousand.
"We remain solidly on track for progressing our technical and business plans to support a specialty products business based on our Camelina platform," said Oliver Peoples, Ph.D., president and chief executive officer of Yield10 Bioscience. "During 2021, we will scale-up seed production of certain new Camelina varieties as well as evaluate our novel yield traits in multi-site field trials conducted in... More
